Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96DI7
UPID:
SNR40_HUMAN
Alternative names:
38 kDa-splicing factor; Prp8-binding protein; U5 snRNP-specific 40 kDa protein; WD repeat-containing protein 57
Alternative UPACC:
Q96DI7; B4DQJ1; O75938; O95320
Background:
The U5 small nuclear ribonucleoprotein 40 kDa protein, also known as 38 kDa-splicing factor, Prp8-binding protein, U5 snRNP-specific 40 kDa protein, and WD repeat-containing protein 57, plays a crucial role in pre-mRNA splicing. It is a component of the activated spliceosome, essential for the splicing of U12-type introns in pre-mRNAs. This protein is part of the U5 snRNP and the U4/U6-U5 tri-snRNP complexes, fundamental for spliceosome assembly.
Therapeutic significance:
Understanding the role of U5 small nuclear ribonucleoprotein 40 kDa protein could open doors to potential therapeutic strategies.